Clinical programs for inhaled insulin have received several setbacks of late, with Bagsværd, Denmark-based Novo Nordisk deciding in January to terminate phase 3 trials of its inhaler and ...
After 11 years of development and barely one full year of sales, New York–based Pfizer dumped the much-anticipated inhaled powder insulin product Exubera on 18 October. This was particularly bad ...
We investigated whether a basal/bolus insulin regimen involving rapid-acting, dry powder, inhaled insulin could provide glycemic control comparable with a basal/bolus subcutaneous regimen.
Initial recommended doses for inhaled insulin were based on the subject's weight, baseline subcutaneous insulin dose, and previous response to insulin. Administration of insulin, inhaled or ...
New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果